BioCryst Pharmaceuticals | BCRX - Net Income


BioCryst Pharmaceuticals reported $245.84M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Chugai Pharma JPY 128.41B 17.2B Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novavax USD 17.53M 219.91M Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025